Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Exanta NDA dropped due to liver injury

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

AstraZeneca withdraws pending NDA for anticoagulant Exanta (ximelagatran) following a report of serious liver injury, the firm announces Feb. 14. The company also is discontinuing two ongoing trials and will switch Exanta-treated patients to other therapies. The decision was triggered by new findings in the EXTEND trial for prevention of venous thromboembolism following orthopedic surgery. Exanta had received a "not approvable" letter in October 2004 in the wake of an advisory committee recommendation against approval due to liver toxicity concerns. The firm has a backup compound - AZD 0837 - in Phase II studies (1Pharmaceutical Approvals Monthly February 2005, p. 20)...

You may also be interested in...

Drug-Induced Liver Injury Workshop Offers More Questions Than Answers

FDA co-hosts a two-day conference to address questions raised by pharmaceutical company comments on the agency's draft guidance on studying drug-induced liver injury. While FDA, industry and academics agreed that patients with underlying liver disease should be included in trials in order to better test a real-world population, there is no consensus on how to do so safely

Symbicort NDA On-Track, Exanta Decision Set For Second-Half – AstraZeneca

AstraZeneca will submit additional data for Symbicort inhalation delivery device. Hold-up comes in wake of setbacks for Iressa, Exanta and Crestor

ESMO: Evidence Piles Up For AZ’s Tagrisso With ADAURA CNS Data

A new analysis of the ADAURA study shows that Tagrisso’s disease-free survival benefits in early stage EGFRm NSCLC are replicated for brain metastases, a common complication with a poor prognosis. Filings and OS data await.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts